| Identification | Back Directory | [Name]
Cicaprost | [CAS]
94079-80-8 | [Synonyms]
ZK-96480
13,14-Didehydro-16,20-dimethyl-3-oxa-18,18,19,19-tetradehydro-6-carbaprostaglandin I2
5-(7-Hydroxy-6-(3-hydroxy-4-methylnona-1,6-diynyl)-bicyclo(3.3.0)octan-3-yliden)-3-oxapentanoic acid
2-[(2E,3aβ,6aβ)-4β-[(3S,4S)-3-Hydroxy-4-methyl-1,6-nonadiynyl]-5α-hydroxyoctahydropentalene-2-ylidene]ethoxyacetic acid
[2-[(2E,3aβ,4S,6aβ)-4β-[(3S,4S)-3-Hydroxy-4-methyl-1,6-nonadiynyl]-5α-hydroxyoctahydropentalene-2-ylidene]ethoxy]acetic acid
[2-[[(2E,3aS,3aβ,6aβ)-5α-Hydroxy-4β-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonanediynyl]octahydropentalen]-2-ylidene]ethoxy]acetic acid
Acetic acid, ((2E)-2-((3as,4S,5R,6as)-hexahydro-5-hydroxy-4-((3S,4S)-3-hydroxy-4-methyl-1,6-nonadiynyl)-2(1H)-pentalenylidene)ethoxy)-
2-[2-[(2E,3aS,4S,5R,6aS)-Hexahydro-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-Methyl-1,6-nonadiyn-1-yl]-2(1H)-pentalenylidene]ethoxy]acetic Acid
Acetic acid, 2-[2-[(2E,3aS,4S,5R,6aS)-hexahydro-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiyn-1-yl]-2(1H)-pentalenylidene]ethoxy]-
Acetic acid, (2-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl)-2(1H)-pentalenylidene)ethoxy)-, (3as-(2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha))- | [Molecular Formula]
C22H30O5 | [MOL File]
94079-80-8.mol | [Molecular Weight]
374.47 |
| Chemical Properties | Back Directory | [Boiling point ]
591.1±50.0 °C(Predicted) | [density ]
1.20±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30 mg/ml; DMSO: 25 mg/ml; Ethanol: 30 mg/ml; PBS (pH 7.2): 1 mg/ml | [pka]
3.41±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
A highly potent anti-metastatic Prostacyclin (P839060) analogue. | [Definition]
ChEBI: Cicaprost is a monoterpenoid. | [in vivo]
Cicaprost alters pain perception and inflammatory response in mice lacking prostacyclin receptor. Intravenous injection of Cicaprost (1 μg/kg) causes hypotension of ～30 mm Hg in anaesthetized wild-type mice[4]. | Animal Model: | Wild-type (+/+) and IP?/? mice[4] | | Dosage: | 1 μg/kg | | Administration: | Intravenous injection | | Result: | Caused hypotension of ～30 mm Hg in anaesthetized wild-type mice, whereas there was no change in blood pressure in IP-deficient mice even at 10 μg/kg. |
| [IC 50]
IP |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Carbosynth
|
| Tel: |
+86 512 6260 5585 |
| Website: |
www.carbosynth.com |
|